...
首页> 外文期刊>Trials >Safety and effectiveness evaluation of a domestic peritoneal dialysis fluid packed in non-PVC bags: study protocol for a randomized controlled trial
【24h】

Safety and effectiveness evaluation of a domestic peritoneal dialysis fluid packed in non-PVC bags: study protocol for a randomized controlled trial

机译:用非PVC袋包装的家用腹膜透析液的安全性和有效性评估:一项随机对照试验的研究方案

获取原文

摘要

Background Peritoneal dialysis is an important type of renal replacement therapy for uremic patients. In peritoneal dialysis, fluids fill in and flow out of the abdominal cavity three to five times per day. Usually, the fluid is packed in a polyvinyl chloride (PVC) bag. Safety concerns have arisen over di-(2-ethylhexyl) phthalate, which is essential in the formation of PVC materials. In 2011, the National Development and Reform Commission of China released a catalog of industrial structural adjustments, mandating the elimination of PVC bags for intravenous infusion and food containers. Although bags for peritoneal dialysis fluid were not included in the elimination list, several manufacturers began to develop new materials for fluid bags. HUAREN peritoneal dialysis fluid consists of the same electrolytes and buffer agent as in Baxter fluid, but is packed in bags that do not contain PVC. This multicenter randomized controlled trial was designed to compare peritoneal dialysis fluid packed in non-PVC-containing and PVC-containing bags. Further, the study sought to determine the proper dose of peritoneal dialysis fluid and the actual survival rates of Chinese patients undergoing peritoneal dialysis. Methods/Design The study participants are adults undergoing continuous ambulatory peritoneal dialysis for 30?days to 6?months. All eligible patients are randomized (1:1) to peritoneal dialysis with Baxter and HUAREN dialysis fluids (initial dose, 6?l/day), with dosages adjusted according to a unified protocol. The primary outcomes are the 1-, 2-, 3-, 4-, and 5-year overall survival rates. Secondary outcome measures include technique survival rates, reductions in estimated glomerular filtration rate, nutritional status, quality of life, cardiovascular events, medical costs and drop-out rates. Safety outcome measures include adverse events, changes in vital signs and laboratory parameters, peritonitis, allergies, and quality of products. Discussion This study is the first to evaluate the long-term safety and effectiveness of a non-PVC packed peritoneal dialysis fluid. The effects of plasticizer on patient long-term survival will be determined. The characteristics of Chinese patients undergoing peritoneal dialysis will be determined, including proper dose, technique survival rates, patient survival rates, and medical costs. Trial registration Clinicaltrials.gov NCT01779557 .
机译:背景技术腹膜透析是尿毒症患者肾脏替代治疗的一种重要类型。在腹膜透析中,液体每天填充和流出腹腔三到五次。通常,将流体包装在聚氯乙烯(PVC)袋中。邻苯二甲酸二(2-乙基己基)酯已引起安全问题,这在PVC材料的形成中至关重要。 2011年,国家发改委发布了产业结构调整目录,要求取消用于静脉输液和食品容器的PVC袋。尽管用于腹膜透析液的包装袋未包括在淘汰清单中,但一些制造商开始开发用于液体包装袋的新材料。 HUAREN腹膜透析液由与百特流体相同的电解质和缓冲剂组成,但包装在不含PVC的袋子中。该多中心随机对照试验旨在比较包装在不含PVC和含PVC的袋中的腹膜透析液。此外,该研究试图确定腹膜透析液的适当剂量以及接受腹膜透析的中国患者的实际生存率。方法/设计研究对象是接受连续非卧床腹膜透析30天至6个月的成年人。将所有符合条件的患者随机(1:1)进行百特和HUAREN透析液(初始剂量6?l /天)进行腹膜透析,并根据统一方案调整剂量。主要结果是1、2、3、4和5年的总生存率。次要结局指标包括技术存活率,估计的肾小球滤过率降低,营养状况,生活质量,心血管事件,医疗费用和辍学率。安全结果措施包括不良事件,生命体征和实验室参数变化,腹膜炎,过敏和产品质量。讨论本研究是第一个评估非PVC填充腹膜透析液的长期安全性和有效性的研究。将确定增塑剂对患者长期生存的影响。将确定接受腹膜透析的中国患者的特征,包括适当的剂量,技术存活率,患者存活率和医疗费用。试用注册Clinicaltrials.gov NCT01779557。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号